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Abstract: Lacosamide (LCM) is a novel agent that has been developed as an antiepileptic drug. 
In vitro studies suggest that LCM modulates voltage-gated sodium channels by enhancing their 
slow inactivation. In addition, LCM seems to interact with collapsin-response mediator protein 2 
and thus may mediate neuronal plasticity. LCM has an elimination half-life of 13 hours, no 
relevant protein binding, and does not induce or inhibit enzymes of the cytochrome P450 system. 
No clinically significant drug–drug interactions have been discovered as yet. Experimental data 
suggest anticonvulsant as well as analgesic effects. Large clinical studies have demonstrated 
its efficacy for treatment of patients with partial seizures. LCM is well tolerated, and the most 
common adverse events are unspecific central nervous system and gastrointestinal effects such 
as dizziness, vertigo, nausea, and headache. LCM is approved for treatment of partial seizures 
with or without secondary generalization in the United States and the European Union within a 
dose range of 200 to 400 mg per day, administered twice daily. In addition to the oral formula-
tions, an intravenous infusion solution is available.
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Introduction
Epilepsy is a frequent neurological disorder that is defined as the “… enduring 
predisposition of the brain to generate epileptic seizures …”.1 Usually, this definition is 
operationalized as the occurrence of two or more unprovoked seizures. Epidemiologic 
studies have shown that approximately 0.5% to 1% of the general population suffer 
from epilepsy,2,3 with annual incidence rates of approximately 30 to 50 per 100,000 
per year.2 Epilepsy is not a distinct disease entity, but a common final pathway of a 
large variety of different etiologies. It can be described as the repetitive occurrence 
of abnormal bioelectrical synchronization of a large number of neurons leading to 
temporary dysfunction of one or more brain areas.
Application of antiepileptic drugs (AEDs) is the mainstay of treatment for most 
patients. Although almost 50% of the patients become seizure free with the first AED 
regardless of the agent,4 a substantial proportion of patients still have inadequate seizure 
control in spite of treatment with currently available AEDs. Therefore, there is still a 
need for new AED with enhanced effectiveness, tolerability, and/or pharmacokinetic 
properties.5
Lacosamide (LCM) is a novel AED that has recently been licensed for adjunctive 
therapy of partial or secondary generalized seizures in the US as well as many European 
countries. This review summarizes the available pharmacological and clinical data 
regarding this new agent.Therapeutics and Clinical Risk Management 2009:5 758
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Chemistry and mechanisms 
of action
LCM (formerly referred to as SPM927, Harkoseride, or 
ADD 234037), is the leading drug of a novel class of AEDs 
termed functionalized amino acids6 which have been screened 
for anticonvulsant properties.7–10 The active substance 
is (R)-2-acetamido-N-benzyl-3-methoxyproionamide 
(see Figure 1). It is a white to yellow crystalline powder 
with a molecular weight of 250.30 Da and a melting point of 
143 to 144 °C that has high water solubility (20.1 mg/mL in 
phosphate-buffered saline).8,9 The S-stereoisomer was much 
less potent in preclinical studies11 and has not entered more 
advanced phases of drug development.
Extensive binding studies have shown that neither LCM 
nor its metabolites significantly bind to any of the known 
binding sites of other anticonvulsant or analgesic agents.12 
In addition, there was no influence on uptake or metabolism 
of one of the major neurotransmitters.8 In spite of clear 
anticonvulsant properties, the molecular basis of these prop-
erties remained unclear for relatively long time. However, 
current experimental data suggest a dual mechanism of 
action: a) modulation of the slow inactivation of sodium 
channels, and b) modulation of collapsin-response mediator 
protein 2 (CRMP-2)-mediated neurotrophic signals.
Modulation of the slow inactivation 
of sodium channels
Early electrophysiologic studies have shown that LCM mildly 
reduces the spike frequency evoked by somatic current 
injection but did not change spike amplitude or duration.12 
These findings were in contrast to the typical findings seen 
with classical sodium channel-blocking agents such as 
phenytoin and carbamazepine, but suggested a modulation 
of voltage-gated sodium channels (VGSC) of a different type. 
In addition, LCM showed a 25% displacement of an agent 
binding to VGSC site 2. Moreover, LCM seemed to interfere 
preferentially with seizure spread and spontaneous action 
potentials without having any influence on voltage-gated 
Potassium channels or calcium channels.12,13 Finally it could 
be demonstrated that LCM selectively enhances slow inacti-
vation of VGSC, whereas classical sodium channel blocking 
agents produce fast inactivation and/or delay recovery from 
fast inactivation of VGSC without any influence on slow 
inactivation.14 At resting potential, VGSC can be opened by 
depolarization of the membrane potential below a critical 
threshold. The opening leads to influx of sodium ions into 
the cell. Within milliseconds, the channel closes again and is 
now in the fast inactivated state. After repolarization of the 
membrane potential, the channel goes into resting state and 
is again available for opening. In contrast to that, a slight and 
prolonged depolarization can bring the VGSC into the slow 
inactivated state. This process takes seconds to minutes.8 
Whereas classical AEDs enhance the fast inactivated state, 
LCM seems to enhance the slow inactivated state by altering 
the voltage-dependence of the VGSC subunit arrangement. 
Thus LCM reduces the ability of (epileptic) neurons to 
sustain prolonged firing bursts by regulating the long-term 
availability of VGSCs.8,14
Modulation of CRMP-2-mediated 
neurotrophic signals
Proteomic affinity labeling methods and subsequent 
radioligand binding experiments have demonstrated 
CRMP-2 as a binding partner for LCM.8 Proteins of the 
CRMP-family seem to be involved in developmental pro-
cesses of the nervous system. CRMP-2 mediates the trans-
duction of neurotrophic signals to neuronal response and 
thus influences axonal sprouting and as well as neuronal 
differentiation.15 Moreover, CRMP-2 seems to be reduced 
in human hippocampal slices from patients with refractory 
epilepsy, but not in nonepileptic control patients.16 LCM 
inhibits those effects of neurotrophins on axonal outgrowth 
that are CRMP-2-mediated.8 There is additional indirect 
evidence for the role of LCM CRMP-2-modulation, since 
CRMP-2 mediates downregulation of N-methyl-D-aspartate 
(NMDA)-receptor subtype NR2B – a receptor subtype that 
seem to play a role in epileptogenesis.17
Pharmacokinetics, drug interactions
Basic pharmacological properties were assessed in 
phase I studies with healthy volunteers.10,18 Following 
oral administration, single doses of LCM were rapidly 
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and almost completely absorbed.10,18 Maximum plasma 
concentration was reached between 1 and 4 hours after 
intake (mean: 1.5 hours), with linear increase of plasma 
concentration with dose (400 mg: 8.7 ± .8 µg/mL; 600 mg 
14.3 ± 2.3 µg/mL, 800 mg: 19.0 ± 4.8 µg/mL).18,10 Elimination 
half-life was approximately 13 hours. Multiple dosing did 
not change the basic pharmacokinetic properties.18 Con-
comitant administration of food did not influence time 
to maximum plasma concentration or the area under the 
plasma-concentration-time curve (AUC).19 Protein binding 
was 15%.18,20 There was low intra- as well as inter-subject 
variability even across different age groups and gender, with 
subjects above 65 years of age having only slightly shorter 
interval to maximum concentration and higher AUC.21 
Steady-state plasma levels were achieved after three days of 
repeated oral administration. A proportion of LCM (∼30%) is 
metabolized to a O-desmethyl-metabolite that seems to have 
no pharmacological acitivity.22,23 LCM and its metabolites are 
eliminated primarily by kidney.22,23 However, there was only a 
20% increase of AUC in patients with mild to moderate renal 
impairment (ie, creatinin clearance = 30 to 80 mL/min), and 
a 60% increase in patients with severe renal impairment.22 
Administration of LCM to extensive or poor metabolizers 
of the cytochrome P 450 subsystem 2C19 showed that there 
is no relevant effect on metabolization and elimination of 
LCM by this system.20 In spite of this fact, there is a 50% to 
60% increase in the AUC in patients with moderate hepatic 
impairment.22 Therefore, caution is advised in patients with 
hepatic disease.
These properties suggest that there is a low potential 
for pharmacokinetic interactions with other AEDs 
or other drugs. Specific trials showed no interaction 
of LCM and valproate, carbamazepine24 and metfor-
min.25 In addition, LCM did not interact with digoxin, 
omeprazol, estradiol or levonorgestrel.20 There was 
no effect of LCM on concomitant AED plasma levels 
(carbamazepine, lamotrigine, levetiracetam, phenytoin, 
zonisamide, gabapentin, topiramate) in patients enrolled 
in phase I, phase II, and phase III studies20,26–28 with the 
exception of a mild decrease of the monohydroxy-deriva-
tive of oxcarbazepine without clinical relevance (mean 
decrease 4.2 µg/mL) in one of the phase-III trials.28 In 
Table 1 Pharmacokinetic profile
Bioavailability ∼100%
tmax (h, median/range)a 1.5 (1–4)
Cmax (µg/mL) 8.7 (± 1.8)
AUC (µg⋅h/mL) 143 (± 27)
t1/2 (h) 13
Protein-binding 15%
Distribution volume ∼0.6 L/kg
Relation metabolization:unchanged elimination 60:40
Active metabolites no
elimination renal (substance and metabolites)
Influence of concomitant food no
induction/inhibition of Cytochrome P 450 subsystems: no
AUC/Cmax in healthy elderly ∼ +20% compared to young subjects
AUC/Cmax in mild/moderate renal impairment ∼ +25% compared to healthy subjects
AUC/Cmax in severe renal impairment ∼ +60% compared to healthy subjects
AUC/Cmax in mild/moderate hepatic impairment ∼ +50% to 60% compared to healthy subjects
elimination by hemodialysis complete
Relevant drug–drug interaction with anticonvulsants no
Relevant drug–drug interaction with metformin, digoxin, 
estradiol, levonorgestrel, omeprazol
no
Mean plasma concentration in patients completing 
a randomized, multicenter trial
4.99 µg/mL (LCM 200 mg/day) 
9.35 µg/mL (LCM 400 mg/day)
a400 mg single dose in healthy male volunteers.
Abbreviations: tmax, time to maximum plasma concentration; Cmax, maximum plasma concentration; AUC, area under the plasma-concentration-time-curve; t1/2, elimination 
half-life.Therapeutics and Clinical Risk Management 2009:5 760
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contrast to that, a population pharmacokinetic analysis 
of the phase III studies showed that enzyme-inducing 
AEDs such as phenytoin, carbamazepin, or phenobarbital 
reduced the overall systemic exposure to LCM by 15% 
to 20%.22 This information was added to the physician’s 
prescription information, but the analysis itself has not yet 
been published in detail. Its clinical relevance remains to 
be elucidated.
Experimental data on efficacy 
and safety/tolerability
LCM was screened for anticonvulsant effects in range 
of animal models of seizures and epilepsy. In these 
investigations, it demonstrated a unique profile similar 
to some of the newer AEDs, but with several differences. 
Using the Frings audiogenic seizures–susceptible mouse 
model, LCM was protective with an ED50 of 0.63 mg/kg 
(intraperitoneally injected).29 The maximal electroshock 
model (MES) is regarded as screening instrument for inhibi-
tion of seizure spread.30 LCM was effective in the MES in rats 
as well as in mice,8,31 demonstrating its potential to prevent 
secondary generalized seizures. The 6-Hz psychomotor 
seizure test seems to model therapy-resistant epilepsy32 and 
is regarded as complementary to the MES model because of 
different sensitivities to distinct classes of AEDs. In contrast 
to classical VGSC agents, LCM was very effective in the 6-Hz 
psychomotor seizure test with an ED50 of 9.99 mg/kg.8,33 In 
this model, there was also a significant synergistic effect with 
carbamazepine and levetiracetam.8
LCM did not provide protection against seizures provoked 
by most chemoconvulsants such as bicuculline, picrotoxin 
and pentylenetetrazol.8,29 However, LCM elevated the seizure 
threshold in the metrazol-seizure threshold test8,29 and pre-
vented seizures and death in the NMDA-induced convulsion 
test in mice.31
In addition, LCM demonstrated efficacy in a model 
screening for antiepileptic (in contrast to anticonvulsant) 
properties of a medication. In the electrical rapid hippocam-
pal kindling model,34 animals receive repetitive electrical 
stimulation of the hippocampal area successively decreasing 
the seizure threshold for following stimuli. LCM in a dose-
dependent fashion reduced seizure duration seizure severity 
and after discharge duration using doses from 7 mg/kg to 
25 mg/kg.31
In the cobalt/homocysteine model for self-sustaining 
status epilepticus in rats, LCM was able to dose-dependently 
prevent generalized tonic-clonic seizures (ED 50: 45.4 mg/kg). 
The co-administration of diazepam markedly potentiated the 
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Figure 2 Efficacy of lacosamide (LCM) in partial epilepsy. Summary of the results of the phase-III studies of LCM as add-on treatment of patients with partial seizures with or 
without secondary generalization – primary endpoint 1: reduction in seizure frequency per 28 days from baseline to maintenance.
Notes: **P  0.01 *P  0.05Therapeutics and Clinical Risk Management 2009:5 761
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effect of LCM and reduced the ED50 by more than 90% to 
3.85 mg/kg.31
Clinical efficacy and use in epilepsy
Early trials involving patients with epilepsy were open 
label. Their results have been published only in abstract 
form.27,35 In one trial,27 doses were increased from 200 to 
600 mg/day in weekly steps of 200 mg. Eleven of 13 patients 
reached the maximum dose of 600 mg/day, with the most 
common adverse effects of dizziness, headache, ataxia and 
nystagmus (at least 10% of the patients). The following trial35 
included 91 subjects with partial seizures who are taking 
one or two concomitant AEDs. After a baseline of 4 weeks, 
LCM was titrated in increments of 100 mg/week to the 
individual maximum tolerated dose (MTD) and then kept 
stable for 4 weeks. The MTD was between 400 and 600 mg 
in approximately 50% of the patients, with a median MTD 
of 300 mg/day. In 86 patients, seizure data were complete. 
During the 4-week maintenance phase, there was a seizure 
reduction of at least 50% in 33% of the patients, and 10% 
of the patients remained seizure free.
Finally, 3 large randomized controlled trials were 
conducted that provided the mandatory efficacy and safety 
data required for licensing of LCM. The results of 2 of 
these (SP 667, SP 755) have been published as original 
communications in peer-reviewed journals.26,28 The results 
of the third trial (SP754) are available only as an abstract.36
The first large phase III trial26 was conducted as an inter-
national, multicenter, double-blinded, placebo-controlled, 
randomized trial with 3 treatment arms (LCM 200 mg/day, 
LCM 400 mg/day, LCM 600 mg/day) and 1 placebo arm. 
Randomization was performed in a 1:1:1:1 ratio. Eligible 
patients must have had partial seizures for at least the prior 
2 years despite treatment with at least 2 AEDs and a stable 
AED regimen for the last 4 weeks before enrollment. Patients 
were excluded when they fulfilled the typical exclusion criteria 
for trials with investigational AEDs such as history of alcohol 
and drug abuse, nonepileptic seizures, history of idiosyncratic 
drug reactions, relevant medical or psychiatric diseases. Dur-
ing the prospective baseline phase, subjects had to have at 
least 4 partial-onset seizures per 28 days on average. If the 
subjects were eligible for randomization, a 6-week titration 
period and a 12-week maintenance period followed. Titration 
was in steps of 100 mg/week. Primary outcome variables were 
reduction in seizure frequency per 28 days from baseline to 
maintenance, and responder rate (ie, rate of subjects with at 
least 50% reduction of seizure frequency) from baseline to 
maintenance. Of the 497 patients who entered the baseline 
period, 421 were randomized to one of the four treatment 
arms. The intention-to-treat analysis (ITT) showed a median 
45
40
35
30
25
20
15
10
5
0
placebo LMC LMC LMC
SP755
SP754
SP667
** *
*
**
600 mg 400 mg 200 mg
5
0
%
R
e
s
p
o
n
d
e
r
 
r
a
t
e
 
i
n
 
%
**
Figure 3 Efficacy of lacosamide (LCM) in partial epilepsy. Summary of the results of the phase III studies of LCM as add-on treatment of patients with partial seizures with or 
without secondary generalization – primary endpoint 2: responder rate, defined as reduction of at least 50% in seizure frequency from baseline to maintenance.
Notes: **P  0.01 *P  0.05Therapeutics and Clinical Risk Management 2009:5 762
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percent reduction of 40% in the 600 mg/day, 39% in the 
400 mg/day, 26% in the 200 mg/day and 10% in the placebo 
group. Statistical significance was reached only for the 600 
mg/day (P = 0.0023) and the 400 mg/day (P = 0.0084) groups. 
Compared to the responder rate of the placebo group (22%), 
the responder rate of the 600 mg/day group (38%, P = 0.0141) 
and of the 400 mg/day group (41%, P = 0.0038) was signifi-
cantly higher. The difference to the 200 mg/day group (33%, 
P = 0.089) did not reach statistical significance. A total of 7 
patients were seizure free during the maintenance period (1/107 
in the 200 mg/day group, 5/108 in the 400 mg/day group, and 
1/106 in the 600 mg/day group, 0/97 in the placebo group). 
The retention rate was not one of the prespecified outcome 
parameters. However, the retention rate is an important vari-
able because it combines aspects of efficacy as well as of 
tolerability. Eighty-six of 97 patients randomized to placebo 
(89%), 85 of 107 patients randomized to LCM 200 mg/day 
(79%), 80 of 108 patients randomized to LCM 400 mg/day 
(74%), and 61 of 106 patients randomized to LCM 600 mg/day 
(57%) completed the trial.
The second trial28 was also designed as a multinational, 
double-blind, randomized, placebo-controlled trial, but with 
2 treatment arms (LCM 200 mg/day, LCM 400 mg/day) and 
1 placebo arm, with a 1:1:1-randomization into the different 
arms. Baseline period, and eligibility and exclusion criteria were 
the same as in the first trial. However, the titration phase was 
4 weeks, but with the same incremental steps (100 mg/week). 
Maintenance phase was 12 weeks as above. Again, primary 
outcome parameters were change in seizure frequency from 
baseline to maintenance period, and the 50% responder rate.
Of the 584 patients entering the baseline period, 485 patients 
were randomized. However, only those 477 patients that 
received at least 1 dose of trial medication were included in 
the ITT analysis. The ITT analysis showed a median percent 
reduction of seizure frequency of 36% for the LCM 400 mg/day 
group, 35% for the LCM 200 mg/day group, and 21% for 
the placebo group. The differences for both treatment arms 
against placebo reached statistical significance (P = 0.02 for 
LCM 200 mg/day, P = 0.03 for LCM 400 mg/day). The 50% 
responder rate was 41% for the LCM 400 mg/day group, 35% 
for the LCM 200 mg/day group, and 26% for the placebo 
group. Only the difference between the LCM 400 mg/day 
group and placebo was statistically significant. Among those 
completing the maintenance period, 3.6% of the patients 
receiving LCM 200 mg/day, 2.4% of the patients receiving 
400 mg/day, and 2.1% of the patients receiving placebo were 
seizure free. Hundred forty-seven of 163 patients random-
ized to placebo (90%), 136 of 163 patients randomized to 
LCM 200 mg/day (83%), and 122 of 159 patients randomized 
to LCM 400 mg/day (76%) completed the study.
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The third study36 was also designed as multicenter, 
double-blind, randomized, placebo-controlled study but was 
conducted solely in the US. The same inclusion criteria and 
primary outcome variables as in the 2 other large studies, and 
the same length of baseline, titration, and maintenance periods 
as in the first trial were used. A total of 405 patients were ran-
domized in a 1:2:1 proportion to placebo, LCM 400 mg/day 
and LCM 600 mg/day. In the ITT analysis, a median reduc-
tion of seizure frequency of 21% for placebo, 37% for LCM 
400 mg/day and 38% for LCM 600 mg/day was found. 
The 50% responder rate was 18% for the placebo group, 
38% for the LCM 400 mg/day group and 41% for the LCM 
600 mg/day group. The differences between the active arms 
and the placebo arm were significant (P  0.01). No patient of 
the placebo-group, 4 patients of the LCM 400 mg/day group 
(2.5%), and 5 patients of the LCM 600 mg/day group (8%) 
were seizure-free throughout the maintenance period. Reten-
tion rate was 95/104 (91%) for the placebo group, 160/201 
(80%) for the LCM 400 mg/day group, and 62/97 (64%) in 
the LCM 600 mg/day group.
Patients who participated in the large randomized 
controlled trials could opt for transfer into open-label extension 
trials. After titration to a common starting dose of 200 mg/day, 
the patient could receive between 100 mg/day and 800 mg/day, 
according to the individual response. Median seizure reduction 
compared to baseline was 43% after 24 weeks.37
In summary, LCM showed a dose-dependently increas-
ing efficacy and decreasing retention rate. Whereas LCM 
200 mg/day failed to show a statistically significant effect 
compared to placebo in some of the trials and primary 
outcome parameters but had the best retention rates, LCM 
600 mg/day had the lowest retention rates with the efficacy 
not markedly better than LCM 400 mg/day. Therefore, doses 
about 400 mg seem to show the most favorable trade-off 
between efficacy and tolerability.
Safety, tolerability, and adverse 
effects
A study investigating the median tolerated dose with titration 
steps of 100 mg/week35 in 91 patients showed that the most 
frequent adverse events were related to central nervous system 
(CNS) effects such as dizziness (57%), diplopia (23%), fatigue 
(18%), and somnolence (19%). Adverse events concerning 
other body systems were mentioned not more than once and 
included syncope, asthenia, dyspepsia, bundle branch block, 
anxiety, erythematous rash, and abnormal vision. However, 
only 12% of the patients withdrew due to adverse events 
(headache n = 3, dizziness n = 2, hypoaesthesia n = 2, ataxia 
n = 1, seizure n = 1). Median tolerated dose was 300 mg/day, 
most common maximum tolerated dose was 600 mg.
In the large phase III trials, the most frequent dose-related 
adverse events (10% of patients) were seen in the CNS 
(dizziness, headache, fatigue, ataxia, abnormal vision, 
somnolence, ataxia, and diplopia) and gastrointestinal (nausea, 
vomiting) and represent the typical dose-dependent effects 
of AEDs and other CNS-acting drugs.26,28,36,38–40 Withdrawal 
because of adverse events occurred in 5% to 14% of the 
placebo groups, 6% to 11% of the LCM 200 mg/day-groups, 
11% to 24% of the LCM 400 mg/day groups and 27% to 42% 
of the LCM 600 mg/day groups. Adverse events leading to 
discontinuation in more of 1% of the patients were diplopia, 
tremor, vertigo, nausea, vomiting, dizziness, abnormal 
coordination, and nystagmus. Serious adverse events occurred 
in 3 to 7% in the placebo group, 3% to 9% in the LCM 
200 mg/day group, 5% to 10% in the LCM 400 mg/day group, 
and 3% to 10% in the LCM 600 mg/day group. The serious 
adverse events seen in more than 1 patient were (worsening 
of) seizures, psychotic disorders, dizziness, vomiting, accident, 
and nystagmus.26,28 The long-term open-label extension trials 
showed a similar profile of mainly mild to moderate CNS and 
gastrointestinal effects with a drop-out rate due to adverse 
events in 11% to 17% of the patients.41,42
Although the phase I and phase III trials did not show 
a significant change of PR and QTc intervals,43 ECG data 
of the large randomized trials showed a mild increase 
in mean PR interval compared to baseline that seemed 
to be dose-related (4.2 to 12.3 ms at a dose of 400 mg/
day).26,28,36,38–40 However, this was not clinically relevant as 
only 4 of 941 patients of the epilepsy studies,26,28,36 and in 
none of the patients did this PR change lead to drop out. In 
the diabetic painful neuropathy studies, there was a treat-
ment-emergent first-grade atrioventricular block in 2% to 
8% of the patients receiving LCM, but also in 6% of the 
placebo group in 1 trial,39 and in approximately 2% in both 
LCM-receiving groups and placebo. Changes in QTc were 
not reported.26,28,36,38,39 There was no evidence for relevant 
changes of body weight.39
Lacosamide as intravenous solution
LCM iv solution was developed early because of the 
relatively high water solubility of the agent. The avail-
able formulation is a 10 mg/L isotonic solution (pH 3.5 
to 5). It is stable at room temperature, does not need 
protection from light, and can be administered without 
dilution or other preparation.44 Phase-I trials with healthy 
volunteers showed bioequivalence as measured by the area Therapeutics and Clinical Risk Management 2009:5 764
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under the curve (AUC) and maximal concentration (Cmax) 
between LCM 200 mg taken orally or per intravenous 
infusion of 30 minutes and 60 minutes duration.45,46 To 
demonstrate safety and tolerability, a randomized, double-
blind, double-dummy trial was performed.44 Patients were 
recruited from an ongoing open-label extension trial. They 
had to be on a stable dose of oral LCM and the concomitant 
AEDs for at least 4 weeks. Patients were randomized (2:1) 
to receive either iv LCM and placebo tablets twice daily, 
or iv placebo and LCM tablets twice daily. Intravenous 
LCM was administered in 30 minutes in one group, and 
in 60 minutes in the other group. LCM doses ranged from 
200 mg to 600 mg/day, the majority of the patients receiv-
ing 200 mg to 300 mg LCM as single dose. There was no 
significant difference in the number and types of treatment-
emergent adverse events between groups. Pharmacokinetic 
parameters also did not differ.
A second trial was designed as an open-label trial.47 
Patients were also recruited from an ongoing open-label 
extension trial of oral LCM, with the same inclusion and 
exclusion criteria as the previously mentioned trial. Five 
cohorts were planned with varying infusion rates (30, 15, or 
10 minutes) and duration of dosing (2 to 5 days). A safety 
monitoring committee reviewed data from each completed 
cohort prior to initiation of the subsequent cohort. Data of 4 
cohorts have been published in abstract form to date. They 
included 160 patients (30 minutes infusion: n = 40; 160 total 
infusions; 15 minutes infusion: n = 100, 747 total infusions; 
10 minutes infusion: n = 20, 162 total infusions). Sociode-
mographic data were similar across the cohorts. More than 
half of the patients of each cohort received a daily dose of 
LCM ranging from 200 to 400 mg, a third to one half of 
the patients received 500 to 600 mg, and 7 patients of the 
15-minutes group received 700 to 800 mg per day. Across 
the 10-minutes and 15-minutes cohorts, 71% of the subjects 
received iv treatment over 3 to 5 days.
There was 1 serious adverse event reported. One 
subject in the 15-minutes group experienced bradycardia 
for 4 minutes during the second day of LCM iv (300 mg/day) 
that was estimated as possibly related to the infusion. The 
infusions on day 1 of LCM iv had been uneventful. The most 
common adverse events were headache (5% to 8% of all 
subjects), and dizziness (5% to 8%). The severity was rated 
as mild or moderate, and in rated as unrelated to the infusions 
in 80% of the patients. A small increase of PR time in ECG 
was noted that did not differ across cohorts. There was no 
Table 2 Summary of phase III randomized, double-blind, placebo-controlled studies for add-on therapy of lacosamide (LCM) in patients 
with partial epilepsy
Study SP667 SP755 SP754
Published as original report  
(Ben-Menachem et al26)
original report  
(Halasz et al28)
poster  
(Chung et al36)
Number of subjects 
randomized
421 485 405
Time-scale 8 weeks prospective baseline 
6 weeks titration  
12 weeks maintenance
8 weeks prospective baseline 
4 weeks titration 12 weeks 
maintenance
8 weeks prospective baseline 
6 weeks titration 12 weeks 
maintenance
Study arms Placebo  
LCM 200 mg/day  
LCM 400 mg/day  
LCM 600 mg/day
Placebo  
LCM 200 mg/day  
LCM 400 mg/day
Placebo  
LCM 400 mg/day  
LCM 600 mg/day
Randomization scheme placebo, 200 mg, 400 mg, 600 mg 
1:1:1:1
placebo, 200 mg, 400 mg  
1:1:1
placebo, 400 mg, 600 mg  
1:2:1
Number of subjects 
in iTT population
415  
placebo, 200 mg, 400 mg,  
600 mg: 96, 107, 107, 105
477  
placebo, 200 mg, 400 mg: 159, 
160, 158
402  
placebo, 400 mg, 600 mg: 104, 201, 97
Number of subjects 
completed
312  
placebo, 200 mg, 400 mg,  
600 mg: 86, 85, 80 ,61
399  
placebo, 200 mg, 400 mg: 141, 
136, 122
no data
Number of subjects 
discontinued
11, 22, 28, 45  
(11%, 21%, 26%, 43%)
22, 27, 37 (14%, 20%, 23%) no data
Discontinued because 
of adverse events
5, 16, 20 ,32 9, 10, 25 placebo, 400 mg, 600 mg  
5%, 18%, 27%
Abbreviation: iTT, intention-to-treat.Therapeutics and Clinical Risk Management 2009:5 765
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increase in adverse event frequency with shorter infusion 
frequency or greater days of exposure.
Summary and perspectives
LCM is a novel AED that has been approved by the licensing 
authorities in the US and in the European Union for add-on treat-
ment of partial seizures with or without secondary generalization 
in patients of 16 years of age or older at a daily dose of 200 
mg to 400 mg. Its proposed mechanisms of action as well as 
experimental data suggest that there may be synergistic effects 
in combination with other AEDs.8 Its elimination half-life of 
13 hours results in a comparatively easy handling with twice 
daily dosing independent of food intake. LCM plasma levels do 
not show significant variability with gender or age. In addition, 
there are no known relevant pharmacokinetic interactions with 
other AEDs or other relevant agents such as digoxin or estra-
diol. To date, data on efficacy and tolerability in approximately 
1300 patients with epilepsy have been published.48 These data 
show that LCM can effectively reduce seizure burden even in 
patients who have been refractory to modern AEDs such as 
levetiracetam, topiramate, or oxcarbazepine. Retention rates in 
the phase III epilepsy trials have been 75% to 85% in the treat-
ment arms using the currently approved doses. The side effects 
are mainly unspecific CNS and gastrointestinal effects, and mild 
or moderate, and seem to be dose-dependent and associated 
with the titration phase. Idiosyncratic reactions have not been 
observed as of yet. ECG data show a dose-dependent prolonga-
tion of the PR interval of about 5 to 10 ms which is rarely clini-
cally relevant. However, it is recommended that LCM should 
not be used in patients with a pre-existing atrioventricular block 
of grade 1 or 2. Changes of other ECG intervals, particularly 
the QTc interval, are not associated with LCM.
However, available data are mostly from short-term use 
(ie, less than 6 months), and are collected from highly selected 
patients enrolled in clinical trials. No data about the use of 
LCM in clinical practice have been published. In addition, 
data of more than 10,000 patients and long-term application of 
12 or more months are needed to assess more reliably the fre-
quency and severity of rare side effects. Until data from post-
marketing studies, currently ongoing monotherapy studes,48 
and experiences from clinical practice are available, the role 
of LCM within the spectrum of AEDs remains unclear.
LCM has shown analgesic effects in preclinical stud-
ies49 and seemed promising in phase I and phase II studies 
for neuropathic pain in diabetic polyneuropathy. There was 
some effect of LCM also in the following large randomized 
controlled phase III studies. However, this effect failed 
to reach statistical significance for the primary outcome 
parameters in the 200 mg/day arm and in the 600 mg/day 
arms in all of the 3 phase III studies,38–40 and in the 400 mg/
day arm in 1 study.40 As a consequence, LCM has not been 
approved for this indication. It is unknown if there will be 
further trials for neuropathic or other forms of pain.
The intravenous solution of LCM is approved for temporal 
substitution purposes only. Status epilepticus is a neurological 
emergency that frequently requires rapid treatment of unre-
sponsive patients with intravenous application of anticon-
vulsive agents. However, only few of the available drugs are 
explicitly licensed for treatment of status epilepticus, and 
most of them such as phenytoin or thiopental carry a high 
risk of adverse event or require artificial ventilation, or both. 
Therefore, any AED that is available as intravenous formula-
tion is a potential candidate for treatment of status epilepticus, 
particularly if standard drugs fail or are unsuitable. Lacosamid 
iv solution is easy to handle, and has the same safety profile as 
its oral formulation. It is not surprising that it already has been 
used successfully as off-label therapy for status epilepticus.50,51 
However, prospective trials are needed to assess the efficacy 
and safety of LCM for this indication.
Disclosure
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